Impact of central nervous system metastasis after complete resection of lung adenocarcinomas harboring common EGFR mutation – A real-world database study in Japan: The CReGYT-01 EGFR study
European Journal of Cancer · 2024
DOI: 10.1016/j.ejca.2024.113951 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Shinya Katsumata und 42 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Surgery, Shizuoka Cancer Center, Shizuoka, Japan. Electronic address: shi.katsumata@scchr.jp. Hauptthemen laut MEDLINE: Lung Neoplasms, Antineoplastic Agents, Adenocarcinoma of Lung, Central Nervous System Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: To clarify the impact of central nervous system (CNS) metastasis on performance status (PS) at relapse, on subsequent treatment(s), and on survival of patients with lung adenocarcinoma harboring common epidermal growth factor receptor (EGFR) mutation. METHODS: We conducted the multicenter real-world database study for patients with radical resections for lung adenocarcinomas between 2015 and 2018 at 21 centers in Japan. EGFR mutational status was examined at each center. RESULTS: Of 4181 patients enrolled, 1431 underwent complete anatomical resection for lung adenocarcinoma harboring common EGFR mutations. Three-hundred-and-twenty patients experienced disease relapse, and 78 (24%) had CNS metastasis. CNS metastasis was significantly more frequent in patients with conventional adjuvant chemotherapy than those without (30% vs. 20%, P = 0.036). Adjuvant chemotherapy did not significantly improve relapse-free survival at any pathological stage (adjusted hazard ratio for stage IA2-3, IB, and II-III was 1.363, 1.287, and 1.004, respectively). CNS metastasis did not affect PS at relapse. Subsequent treatment, mainly consisting of EGFR-tyrosine kinase inhibitors (TKIs), could be equally given in patients with or without CNS metastasis (96% vs. 94%). Overall survival after relapse was equivalent between patients with and without CNS metastasis. CONCLUSION: The efficacy of conventional adjuvant chemotherapy may be limited in patients with lung adenocarcinoma harboring EGFR mutations. CNS metastasis is likely to be found in practice before deterioration in PS, and may have little negative impact on compliance with subsequent EGFR-TKIs and survival after relapse. In this era of adjuvant TKI therapy, further prospective observational studies are desirable to elucidate the optimal management of CNS metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Thoracic Surgery, Shizuoka Cancer Center, Shizuoka, Japan. Electronic address: shi.katsumata@scchr.jp.
- Department of Biostatistics, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan.
- Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Department of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
- Department of Thoracic Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Zitieren
APA
Katsumata, S., Shimokawa, M., Hamada, A., Haratake, N., Nomura, K., Fujino, K., Yoshikawa, M., Suzawa, K., Shien, K., Suda, K., Ohara, S., Fukuda, S., Kinoshita, F., Hayasaka, K., Notsuda, H., Takamori, S., Muto, S., Takanashi, Y., Mizuno, K., …, & Ohde, Y. (2024). Impact of central nervous system metastasis after complete resection of lung adenocarcinomas harboring common EGFR mutation – A real-world database study in Japan: The CReGYT-01 EGFR study. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.113951
Vancouver
Katsumata S, Shimokawa M, Hamada A, Haratake N, Nomura K, Fujino K, et al. Impact of central nervous system metastasis after complete resection of lung adenocarcinomas harboring common EGFR mutation – A real-world database study in Japan: The CReGYT-01 EGFR study. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.113951
BibTeX
@article{Katsumata2024,
author = {Katsumata, Shinya and Shimokawa, Mototsugu and Hamada, Akira and Haratake, Naoki and Nomura, Kotaro and Fujino, Kosuke and Yoshikawa, Mao and Suzawa, Ken and Shien, Kazuhiko and Suda, Kenichi and Ohara, Shuta and Fukuda, Shota and Kinoshita, Fumihiko and Hayasaka, Kazuki and Notsuda, Hirotsugu and Takamori, Shinkichi and Muto, Satoshi and Takanashi, Yusuke and Mizuno, Kiyomichi and Kawase, Akikazu and Hayakawa, Takamitsu and Sekihara, Keigo and Toda, Michihito and Matsuo, Somei and Takegahara, Kyoshiro and Hashimoto, Masaki and Nakahashi, Kenta and Endo, Makoto and Ozawa, Hiroki and Fujikawa, Ryo and Tomioka, Yasuaki and Namba, Kei and Matsubara, Taichi and Suzuki, Jun and Watanabe, Hikaru and Takada, Kazuki and Hoshino, Hironobu and Kaiho, Taisuke and Toyoda, Takahide and Kouki, Yasunobu and Shiono, Satoshi and Soh, Junichi and Ohde, Yasuhisa},
title = {Impact of central nervous system metastasis after complete resection of lung adenocarcinomas harboring common EGFR mutation – A real-world database study in Japan: The CReGYT-01 EGFR study},
journal = {European Journal of Cancer},
year = {2024},
doi = {10.1016/j.ejca.2024.113951}
}
EUVIMED